An increased CXCL10 and its corresponding receptor, CXCR3, are positively associated with malignant melanoma [55], ovarian carcinoma [56], multiple myeloma [57], B-cell lymphoma [58], and basal cell carcinoma [59]. Here, CXCL10 is linked to plasma cell myeloma.